Related references
Note: Only part of the references are listed.Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications
Peter J. Neumann et al.
VALUE IN HEALTH (2022)
Patients' Access to 2018 FDA-Approved Drugs 1 Year Post
Ari D. Panzer et al.
AMERICAN JOURNAL OF MANAGED CARE (2022)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Patent term restoration for top-selling drugs in the United States
Reed F. Beall et al.
DRUG DISCOVERY TODAY (2019)
Prices of Generic Drugs Associated with Numbers of Manufacturers
Chintan V. Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs
Anastasia Khvorova
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations
Ernst R. Berndt et al.
HEALTH AFFAIRS (2015)
Utilization, price, and spending trends for antidepressants in the US Medicaid program
Yan Chen et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2008)
Generic Competition and Market Exclusivity Periods in Pharmaceuticals
Henry G. Grabowski et al.
MANAGERIAL AND DECISION ECONOMICS (2007)
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics
LA Prosser et al.
ANNALS OF INTERNAL MEDICINE (2000)